A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Ontology highlight
ABSTRACT: This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
DISEASE(S): Solid Tumor,Glioblastome Multiforme,Colorectal Cancer,Breast Neoplasms,Breast Cancer
PROVIDER: 2322657 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA